Wirkstoffe & Arzneimittelsicherheit

Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.

RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.

Quellenpassagen (78)

Wechselwirkungen · Taxotere

TAXOTERE 20 mg/0.5 mL concentrate and solvent for solution for infusion · Abschnitt 4.5 · PDF-Seite 11

HOS-084515 · Präparat HOS-083047

In case of combination with CYP3A4 inhibitors, the occurrence of docetaxel adverse reactions may increase, as a result of reduced metabolism. If the concomitant use of a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) cannot be avoided, a close clinical surveillance is warranted and a dose-adjustment of docetaxel may be suitable during the treatment with the strong CYP3A4 inhibitor (see section 4.4). In a pharmacokinetic study with 7 patients, the co-administration of docetaxel with the strong CYP3A4 inhibitor ketoconazole leads to a significant decrease in docetaxel clearance by 49%.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) itraconazole (HOS-084516) clarithromycin (HOS-084517) indinavir (HOS-084518) nefazodone (HOS-084519) nelfinavir (HOS-084520) ritonavir (HOS-084521) saquinavir (HOS-084522) telithromycin (HOS-084523) voriconazole (HOS-084524)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage f640897b581648a671549528599a0e77c0e915b1bc7804c45ad024fcf812c54f · Zeichen 564–1272 im Abschnitt

Wechselwirkungen · Taxotere

TAXOTERE 80 mg/2 mL concentrate and solvent for solution for infusion · Abschnitt 4.5 · PDF-Seite 55

HOS-084650 · Präparat HOS-083047

In case of combination with CYP3A4 inhibitors, the occurrence of docetaxel adverse reactions may increase, as a result of reduced metabolism. If the concomitant use of a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) cannot be avoided, a close clinical surveillance is warranted and a dose-adjustment of docetaxel may be suitable during the treatment with the strong CYP3A4 inhibitor (see section 4.4). In a pharmacokinetic study with 7 patients, the co-administration of docetaxel with the strong CYP3A4 inhibitor ketoconazole leads to a significant decrease in docetaxel clearance by 49%.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clarithromycin (HOS-084517) indinavir (HOS-084518) nefazodone (HOS-084519) nelfinavir (HOS-084520) ritonavir (HOS-084521) saquinavir (HOS-084522) telithromycin (HOS-084523) voriconazole (HOS-084524) ketoconazole (HOS-084513) itraconazole (HOS-084516)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Wechselwirkungen · Taxotere

TAXOTERE 20 mg/1 mL concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 100

HOS-084764 · Präparat HOS-083047

In case of combination with CYP3A4 inhibitors, the occurrence of docetaxel adverse reactions may increase, as a result of reduced metabolism. If the concomitant use of a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) cannot be avoided, a close clinical surveillance is warranted and a dose-adjustment of docetaxel may be suitable during the treatment with the strong CYP3A4 inhibitor (see section 4.4). In a pharmacokinetic study with 7 patients, the co-administration of docetaxel with the strong CYP3A4 inhibitor ketoconazole leads to a significant decrease in docetaxel clearance by 49%.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Wechselwirkungen · Taxotere

TAXOTERE 80 mg/4 mL concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 144

HOS-084876 · Präparat HOS-083047

In case of combination with CYP3A4 inhibitors, the occurrence of docetaxel adverse reactions may increase, as a result of reduced metabolism. If the concomitant use of a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) cannot be avoided, a close clinical surveillance is warranted and a dose-adjustment of docetaxel may be suitable during the treatment with the strong CYP3A4 inhibitor (see section 4.4). In a pharmacokinetic study with 7 patients, the co-administration of docetaxel with the strong CYP3A4 inhibitor ketoconazole leads to a significant decrease in docetaxel clearance by 49%.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Wechselwirkungen · Taxotere

TAXOTERE 160 mg/8 mL concentrate for solution for infusion. · Abschnitt 4.5 · PDF-Seite 189

HOS-084986 · Präparat HOS-083047

In case of combination with CYP3A4 inhibitors, the occurrence of docetaxel adverse reactions may increase, as a result of reduced metabolism. If the concomitant use of a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) cannot be avoided, a close clinical surveillance is warranted and a dose-adjustment of docetaxel may be suitable during the treatment with the strong CYP3A4 inhibitor (see section 4.4). In a pharmacokinetic study with 7 patients, the co-administration of docetaxel with the strong CYP3A4 inhibitor ketoconazole leads to a significant decrease in docetaxel clearance by 49%.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521) saquinavir (HOS-084522) telithromycin (HOS-084523) voriconazole (HOS-084524) nelfinavir (HOS-084520) ketoconazole (HOS-084513) itraconazole (HOS-084516) clarithromycin (HOS-084517) indinavir (HOS-084518) nefazodone (HOS-084519)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Wechselwirkungen · Rapamune

Rapamune 1 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 10

HOS-090616 · Präparat HOS-084095

Inhibitors of CYP3A4 may decrease the metabolism of sirolimus and increase sirolimus blood levels. Such inhibitors include certain antifungals (e.g. clotrimazole, fluconazole, itraconazole, voriconazole), certain antibiotics (e.g. troleandomycin, telithromycin, clarithromycin), certain protease inhibitors (e.g. ritonavir, indinavir, boceprevir, telaprevir), nicardipine, bromocriptine, cimetidine, danazol and letermovir.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) boceprevir (HOS-090617) telaprevir (HOS-090618) nicardipine (HOS-090619) bromocriptine (HOS-090620) cimetidine (HOS-085835) danazol (HOS-085473) letermovir (HOS-090621) clotrimazole (HOS-090574) fluconazole (HOS-087945) itraconazole (HOS-084516) voriconazole (HOS-084524) troleandomycin (HOS-090575) telithromycin (HOS-084523) clarithromycin (HOS-084517) protease (HOS-085623) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 5e78d73fd3b12aea3ede2eeac1a14a3dfb8e863d7c5ea6929177114d000b7a9c · Zeichen 5491–5914 im Abschnitt

Wechselwirkungen · Rapamune

Rapamune 0.5 mg coated tablets Rapamune 1 mg coated tablets Rapamune 2 mg coated tablets · Abschnitt 4.5 · PDF-Seite 30

HOS-090685 · Präparat HOS-084095

Inhibitors of CYP3A4 may decrease the metabolism of sirolimus and increase sirolimus blood levels. Such inhibitors include certain antifungals (e.g. clotrimazole, fluconazole, itraconazole, voriconazole), certain antibiotics (e.g. troleandomycin, telithromycin, clarithromycin), certain protease inhibitors (e.g. ritonavir, indinavir, boceprevir, and telaprevir), nicardipine, bromocriptine, cimetidine, danazol and letermovir.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clarithromycin (HOS-084517) protease (HOS-085623) ritonavir (HOS-084521) indinavir (HOS-084518) boceprevir (HOS-090617) telaprevir (HOS-090618) nicardipine (HOS-090619) bromocriptine (HOS-090620) cimetidine (HOS-085835) danazol (HOS-085473) letermovir (HOS-090621) clotrimazole (HOS-090574) fluconazole (HOS-087945) itraconazole (HOS-084516) voriconazole (HOS-084524) troleandomycin (HOS-090575) telithromycin (HOS-084523)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 238f7546225e192c0d4817ab6a1671062b9e93e1fd99e257fa0ce448f21b38a0 · Zeichen 5433–5860 im Abschnitt

Wechselwirkungen · Glivec

Glivec 100 mg film-coated tablets Glivec 400 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10

HOS-110215 · Präparat HOS-093339

Substances that inhibit the cytochrome P450 isoenzyme CYP3A4 activity (e.g. protease inhibitors such as indinavir, lopinavir/ritonavir, ritonavir, saquinavir, telaprevir, nelfinavir, boceprevir; azole antifungals including ketoconazole, itraconazole, posaconazole, voriconazole; certain macrolides such as erythromycin, clarithromycin and telithromycin) could decrease metabolism and increase imatinib concentrations. There was a significant increase in exposure to imatinib (the mean Cmax and AUC of imatinib rose by 26% and 40%, respectively) in healthy subjects when it was co-administered with a single dose of ketoconazole (a CYP3A4 inhibitor). Caution should be taken when administering Glivec with inhibitors of the CYP3A4 family.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clarithromycin (HOS-084517) telithromycin (HOS-084523) protease (HOS-085623) indinavir (HOS-084518) lopinavir (HOS-086269) ritonavir (HOS-084521) saquinavir (HOS-084522) telaprevir (HOS-090618) nelfinavir (HOS-084520) boceprevir (HOS-090617) ketoconazole (HOS-084513) itraconazole (HOS-084516) posaconazole (HOS-085622) voriconazole (HOS-084524) erythromycin (HOS-084514)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-11-12T09:28:00Z · SHA-256 838bc114dc50fcc5141e52ce7cbac64366b6fd4a03bb5a5e7a5ec09cf8be0b00 · Passage 8b33adeac7a33ce76a3ed583287cd02ab3b3048c12d43838a030dbd58a7f3ff4 · Zeichen 68–805 im Abschnitt

Gegenanzeigen · Procoralan

Procoralan 5 mg film-coated tablets Procoralan 7.5 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 4

HOS-113843 · Präparat HOS-093985

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 - Resting heart rate below 70 beats per minute prior to treatment - Cardiogenic shock - Acute myocardial infarction - Severe hypotension (< 90/50 mmHg) - Severe hepatic insufficiency - Sick sinus syndrome - Sino-atrial block - Unstable or acute heart failure - Pacemaker dependent (heart rate imposed exclusively by the pacemaker) - Unstable angina - AV-block of 3rd degree - Combination with strong cytochrome P450 3A4 inhibitors such as azole antifungals (ketoconazole, itraconazole), macrolide antibiotics (clarithromycin, erythromycin per os, josamycin, telithromycin), HIV protease inhibitors (nelfinavir, ritonavir) and nefazodone (see sections 4.5 and 5.2) - Combination with verapamil or diltiazem which are moderate CYP3A4 inhibitors with heart rate reducing properties (see section 4.5) - Pregnancy, lactation and women of childbearing potential not using appropriate contraceptive measures (see section 4.6)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) verapamil (HOS-090602) ketoconazole (HOS-084513) itraconazole (HOS-084516) clarithromycin (HOS-084517) erythromycin (HOS-084514) josamycin (HOS-113844) telithromycin (HOS-084523) protease (HOS-085623) nelfinavir (HOS-084520) ritonavir (HOS-084521) nefazodone (HOS-084519)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-11-17T17:49:00Z · SHA-256 603a04f5264f2cd02119b9fdddd8869a5b599fbe491c4482b048613e56f12c88 · Passage 038375aab2cfa48edaa49949d6504dd4b3dd7e1bb3de22461a40ede8afbd9e21 · Zeichen 0–1101 im Abschnitt

Wechselwirkungen · Procoralan

Procoralan 5 mg film-coated tablets Procoralan 7.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-113857 · Präparat HOS-093985

Potent CYP3A4 inhibitors The concomitant use of potent CYP3A4 inhibitors such as azole antifungals (ketoconazole, itraconazole), macrolide antibiotics (clarithromycin, erythromycin per os, josamycin, telithromycin), HIV protease inhibitors (nelfinavir, ritonavir) and nefazodone is contraindicated (see section 4.3). The potent CYP3A4 inhibitors ketoconazole (200 mg once daily) and josamycin (1 g twice daily) increased ivabradine mean plasma exposure by 7 to 8 fold.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) itraconazole (HOS-084516) clarithromycin (HOS-084517) erythromycin (HOS-084514) josamycin (HOS-113844) telithromycin (HOS-084523) protease (HOS-085623) nelfinavir (HOS-084520) ritonavir (HOS-084521) nefazodone (HOS-084519)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-11-17T17:49:00Z · SHA-256 603a04f5264f2cd02119b9fdddd8869a5b599fbe491c4482b048613e56f12c88 · Passage aeaa075c35dab068c8abda0e4149b350417abc81fdb40d791dd92a17cfbddc6b · Zeichen 1885–2353 im Abschnitt

Gegenanzeigen · Corlentor

Corlentor 5 mg film-coated tablets Corlentor 7.5 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 4

HOS-113882 · Präparat HOS-093993

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 - Resting heart rate below 70 beats per minute prior to treatment - Cardiogenic shock - Acute myocardial infarction - Severe hypotension (< 90/50 mmHg) - Severe hepatic insufficiency - Sick sinus syndrome - Sino-atrial block - Unstable or acute heart failure - Pacemaker dependent (heart rate imposed exclusively by the pacemaker) - Unstable angina - AV-block of 3rd degree - Combination with strong cytochrome P450 3A4 inhibitors such as azole antifungals (ketoconazole, itraconazole), macrolide antibiotics (clarithromycin, erythromycin per os, josamycin, telithromycin), HIV protease inhibitors (nelfinavir, ritonavir) and nefazodone (see sections 4.5 and 5.2) - Combination with verapamil or diltiazem which are moderate CYP3A4 inhibitors with heart rate reducing properties (see section 4.5) - Pregnancy, lactation and women of childbearing potential not using appropriate contraceptive measures (see section 4.6)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): itraconazole (HOS-084516) clarithromycin (HOS-084517) erythromycin (HOS-084514) josamycin (HOS-113844) telithromycin (HOS-084523) protease (HOS-085623) nelfinavir (HOS-084520) ritonavir (HOS-084521) nefazodone (HOS-084519) verapamil (HOS-090602) diltiazem (HOS-086288) ketoconazole (HOS-084513)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-11-17T17:03:00Z · SHA-256 d87e68351dedcde32d83ee33c2f0d9205f341c44bb5b4d122f4a04ffba50a0e0 · Passage 038375aab2cfa48edaa49949d6504dd4b3dd7e1bb3de22461a40ede8afbd9e21 · Zeichen 0–1101 im Abschnitt

Wechselwirkungen · Corlentor

Corlentor 5 mg film-coated tablets Corlentor 7.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-113891 · Präparat HOS-093993

Potent CYP3A4 inhibitors The concomitant use of potent CYP3A4 inhibitors such as azole antifungals (ketoconazole, itraconazole), macrolide antibiotics (clarithromycin, erythromycin per os, josamycin, telithromycin), HIV protease inhibitors (nelfinavir, ritonavir) and nefazodone is contraindicated (see section 4.3). The potent CYP3A4 inhibitors ketoconazole (200 mg once daily) and josamycin (1 g twice daily) increased ivabradine mean plasma exposure by 7 to 8 fold.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-11-17T17:03:00Z · SHA-256 d87e68351dedcde32d83ee33c2f0d9205f341c44bb5b4d122f4a04ffba50a0e0 · Passage aeaa075c35dab068c8abda0e4149b350417abc81fdb40d791dd92a17cfbddc6b · Zeichen 1885–2353 im Abschnitt

Wechselwirkungen · Revatio

Revatio 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-114937 · Präparat HOS-094193

The most potent of the CYP3A4 inhibitors such as ketoconazole and itraconazole would be expected to have effects similar to ritonavir (see section 4.3). CYP3A4 inhibitors like clarithromycin, telithromycin and nefazodone are expected to have an effect in between that of ritonavir and CYP3A4 inhibitors like saquinavir or erythromycin, a seven-fold increase in exposure is assumed. Therefore dose adjustments are recommended when using CYP3A4 inhibitors (see section 4.2).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) itraconazole (HOS-084516) ritonavir (HOS-084521) clarithromycin (HOS-084517) telithromycin (HOS-084523) nefazodone (HOS-084519) saquinavir (HOS-084522) erythromycin (HOS-084514)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-10-13T14:12:00Z · SHA-256 38afb4f2877b63c9a3d5213ff8cb4458ff9d43618600f9ce01caed1bd5a4764f · Passage 1f4082a0a6c5d963b63edd22c10b5845b86bc5ff94e6467a165f0531de78d7d3 · Zeichen 4967–5439 im Abschnitt

Wechselwirkungen · Revatio

Revatio 0.8 mg/ml solution for injection · Abschnitt 4.5 · PDF-Seite 27

HOS-115000 · Präparat HOS-094193

The most potent of the CYP3A4 inhibitors such as ketoconazole and itraconazole would be expected to have effects similar to ritonavir (see section 4.3). CYP3A4 inhibitors like clarithromycin, telithromycin and nefazodone) are expected to have an effect in between that of ritonavir and CYP3A4 inhibitors like saquinavir or erythromycin), a seven-fold increase in exposure is assumed. Therefore dose adjustments are recommended when using CYP3A4 inhibitors (see section 4.2).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): erythromycin (HOS-084514) ketoconazole (HOS-084513) itraconazole (HOS-084516) ritonavir (HOS-084521) clarithromycin (HOS-084517) telithromycin (HOS-084523) nefazodone (HOS-084519) saquinavir (HOS-084522)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-10-13T14:12:00Z · SHA-256 38afb4f2877b63c9a3d5213ff8cb4458ff9d43618600f9ce01caed1bd5a4764f · Passage 481e2c48b4ed56e7321ea948ced45ad338971875626824dcfd615cb657e68f00 · Zeichen 5715–6189 im Abschnitt

Wechselwirkungen · Revatio

Revatio 10 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 45

HOS-115058 · Präparat HOS-094193

The most potent of the CYP3A4 inhibitors such as ketoconazole and itraconazole would be expected to have effects similar to ritonavir (see section 4.3). CYP3A4 inhibitors like clarithromycin, telithromycin and nefazodone are expected to have an effect in between that of ritonavir and CYP3A4 inhibitors like saquinavir or erythromycin, a seven-fold increase in exposure is assumed. Therefore dose adjustments are recommended when using CYP3A4 inhibitors (see section 4.2).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521) clarithromycin (HOS-084517) telithromycin (HOS-084523) nefazodone (HOS-084519) saquinavir (HOS-084522) erythromycin (HOS-084514) ketoconazole (HOS-084513) itraconazole (HOS-084516)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Wechselwirkungen · Sprycel

SPRYCEL 20 mg film-coated tablets SPRYCEL 50 mg film-coated tablets SPRYCEL 70 mg film-coated tablets SPRYCEL 80 mg film-coated tablets SPRYCEL 100 mg film-coated tablets SPRYCEL 140 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11

HOS-116681 · Präparat HOS-094467

Active substances that may increase dasatinib plasma concentrations In vitro studies indicate that dasatinib is a CYP3A4 substrate. Concomitant use of dasatinib and medicinal products or substances which potently inhibit CYP3A4 (e.g. ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, telithromycin, grapefruit juice) may increase exposure to dasatinib. Therefore, in patients receiving dasatinib, systemic administration of a potent CYP3A4 inhibitor is not recommended (see section 4.2).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): erythromycin (HOS-084514) clarithromycin (HOS-084517) ritonavir (HOS-084521) telithromycin (HOS-084523) grapefruit juice (HOS-088787) ketoconazole (HOS-084513) itraconazole (HOS-084516)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-10-02T12:05:00Z · SHA-256 c065657005bf3f51d58db1cb5b29a1453d36e1fc897c0adb5e47ed684f07722e · Passage 4b7cd825bd806fe7cb0d08d7e8a48b7de39787bee3636b13d11149364312873c · Zeichen 0–506 im Abschnitt

Wechselwirkungen · Sprycel

SPRYCEL 10 mg/mL powder for oral suspension · Abschnitt 4.5 · PDF-Seite 47

HOS-116736 · Präparat HOS-094467

Active substances that may increase dasatinib plasma concentrations In vitro studies indicate that dasatinib is a CYP3A4 substrate. Concomitant use of dasatinib and medicinal products or substances which potently inhibit CYP3A4 (e.g. ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, telithromycin, grapefruit juice) may increase exposure to dasatinib. Therefore, in patients receiving dasatinib, systemic administration of a potent CYP3A4 inhibitor is not recommended (see section 4.2).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): erythromycin (HOS-084514) clarithromycin (HOS-084517) ritonavir (HOS-084521) telithromycin (HOS-084523) grapefruit juice (HOS-088787) itraconazole (HOS-084516) ketoconazole (HOS-084513)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Wechselwirkungen · Advagraf

Advagraf 0.5 mg prolonged-release hard capsules Advagraf 1 mg prolonged-release hard capsules Advagraf 3 mg prolonged-release hard capsules Advagraf 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 10–11

HOS-116802 · Präparat HOS-094481

10 Drug/Substance Class or Drug interaction effect Recommendations concerning Name co-administration Strong CYP3A4 inhibitors: May increase tacrolimus whole It is recommended that antifungal agents (e.g., blood trough concentrations and concomitant use should be ketoconazole, itraconazole, increase the risk of serious adverse avoided. If co-administration posaconazole, voriconazole), reactions (e.g., nephrotoxicity, of a strong CYP3A4 inhibitor the macrolide antibiotics neurotoxicity, QT prolongation) is unavoidable, consider (e.g., telithromycin, which requires close monitoring omitting the dose of tacrolimus troleandomycin, [see section 4.4]. the day the strong CYP3A4 clarithromycin, josamycin), Rapid and sharp increases in inhibitor is initiated. Reinitiate HIV protease inhibitors tacrolimus levels may occur, as tacrolimus the next day at a (e.g., ritonavir, nelfinavir, early as within 1-3 days after co- reduced dose based on saquinavir), HCV protease administration, despite immediate tacrolimus blood inhibitors (e.g., telaprevir, reduction of tacrolimus dose. concentrations. Changes in boceprevir, and the Overall tacrolimus exposure may both tacrolimus dose and/or combination of ombitasvir increase > 5 fold. When ritonavir dosing frequency should be and paritaprevir with combinations are co-administered, individualized and adjusted as ritonavir, when used with tacrolimus exposure may increase needed based on tacrolimus and without dasabuvir), > 50 fold. Nearly all patients may trough concentrations, which nefazodone, the require a reduction in tacrolimus should be assessed at initiation, pharmacokinetic enhancer dose and temporary interruption of monitored frequently cobicistat, and the kinase tacrolimus may also be necessary. throughout (starting within the inhibitors idelalisib, The effect on tacrolimus blood first few days) and re- ceritinib. concentrations may remain for evaluated on and after Strong interactions have also several days after co-administration completion of the CYP3A4 been observed with the is completed. inhibitor. Upon completion, macrolide antibiotic appropriate dose and dosing erythromycin frequency of tacrolimus should be guided by tacrolimus blood concentrations. Monitor renal function, ECG for QT prolongation, and other side effects closely. Moderate or weak CYP3A4 May increase tacrolimus whole Monitor tacrolimus whole inhibitors: blood trough concentrations and blood trough concentrations antifungal agents (e.g., increase the risk of serious adverse frequently, starting within the fluconazole, isavuconazole, reactions (e.g., neurotoxicity, QT first few days of co- clotrimazole, miconazole), prolongation) [see section 4.4]. A administration. Reduce the macrolide antibiotics rapid increase in tacrolimus level tacrolimus dose if needed [see (e.g., azithromycin), calcium may occur. section 4.2]. Monitor renal channel blockers (e.g., function, ECG for QT nifedipine, nicardipine, prolongation, and other side diltiazem, verapamil), effects closely. amiodarone, danazol, ethinylestradiol, lansoprazole, omeprazole, the HCV antivirals elbasvir/grazoprevir and glecaprevir/pibrentasvir, the CMV antiviral letermovir, and the tyrosine kinase inhibitors nilotinib, crizotinib and imatinib and (Chinese) herbal remedies containing extracts of Schisandra sphenanthera

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) itraconazole (HOS-084516) posaconazole (HOS-085622) voriconazole (HOS-084524) telithromycin (HOS-084523) troleandomycin (HOS-090575) clarithromycin (HOS-084517) josamycin (HOS-113844) protease (HOS-085623) ritonavir (HOS-084521) nelfinavir (HOS-084520) saquinavir (HOS-084522) telaprevir (HOS-090618) boceprevir (HOS-090617) ombitasvir (HOS-110300) paritaprevir (HOS-110301) dasabuvir (HOS-110302) nefazodone (HOS-084519) cobicistat (HOS-088111) idelalisib (HOS-116811) ceritinib (HOS-086215) erythromycin (HOS-084514) fluconazole (HOS-087945) isavuconazole (HOS-085186) clotrimazole (HOS-090574) miconazole (HOS-115630) azithromycin (HOS-088112) calcium (HOS-085615) nifedipine (HOS-086289) nicardipine (HOS-090619) diltiazem (HOS-086288) verapamil (HOS-090602) amiodarone (HOS-085596) danazol (HOS-085473) lansoprazole (HOS-085166) omeprazole (HOS-085912) elbasvir (HOS-108814) grazoprevir (HOS-108815) glecaprevir (HOS-086297) pibrentasvir (HOS-086298) letermovir (HOS-090621) tyrosine (HOS-108875) nilotinib (HOS-086218) crizotinib (HOS-116818) imatinib (HOS-110212)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-02-27T10:10:00Z · SHA-256 0ed42bc08ffe6bd7e6c8ed94445bdb8b8c9971dabe41ef3a899ec75fc2f97c0e · Passage 871fa2c72a31ddd6873cbb2f1b3b0dd9ad898b46eba141ac32a052a178cc3bc9 · Zeichen 3910–8415 im Abschnitt

Wechselwirkungen · Toviaz

TOVIAZ 4 mg prolonged-release tablets TOVIAZ 8 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 5

HOS-117260 · Präparat HOS-094561

Potent CYP3A4 inhibitors Following inhibition of CYP3A4 by co-administration of ketoconazole 200 mg twice daily, Cmax and AUC of the active metabolite of fesoterodine increased 2.0 and 2.3-fold in CYP2D6 extensive metabolisers and 2.1 and 2.5-fold in CYP2D6 poor metabolisers, respectively. Therefore, the maximum dose of fesoterodine should be restricted to 4 mg when used concomitantly with potent CYP3A4 inhibitors (e.g. atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir (and all ritonavir boosted PI-regimens), saquinavir and telithromycin (see sections 4.2 and 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) atazanavir (HOS-086180) clarithromycin (HOS-084517) indinavir (HOS-084518) itraconazole (HOS-084516) nefazodone (HOS-084519) nelfinavir (HOS-084520) ritonavir (HOS-084521) saquinavir (HOS-084522) telithromycin (HOS-084523)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-03-04T15:52:00Z · SHA-256 c9fd9fb2f6c8ee3d5e56c913ba09d40147211dee6df16329539fa6b5e813accb · Passage 679ac7be8f845fe7a62693f49c65460a286580b97dd43cc2c87699cd8e06bb99 · Zeichen 898–1520 im Abschnitt

Wechselwirkungen · Tasigna

Tasigna 50 mg hard capsules Tasigna 150 mg hard capsules Tasigna 200 mg hard capsules · Abschnitt 4.5 · PDF-Seite 10–11

HOS-118202 · Präparat HOS-094783

10 The exposure to nilotinib in healthy subjects was increased 3-fold when co-administered with the strong CYP3A4 inhibitor ketoconazole. Concomitant treatment with strong CYP3A4 inhibitors, including ketoconazole, itraconazole, voriconazole, ritonavir, clarithromycin, and telithromycin, should therefore be avoided (see section 4.4). Increased exposure to nilotinib might also be expected with moderate CYP3A4 inhibitors. Alternative concomitant medicinal products with no or minimal CYP3A4 inhibition should be considered.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clarithromycin (HOS-084517) telithromycin (HOS-084523) ketoconazole (HOS-084513) itraconazole (HOS-084516) voriconazole (HOS-084524) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-12-17T17:21:00Z · SHA-256 efb2ca2c5c7d9a0e740759217e71ff7f08cf3763f8c41f5c02f5d10733d67b3a · Passage aba926163dfe081ecdf5d7d5fd37f48c0c3219fed062f1dfbe4cda3086c034c8 · Zeichen 1026–1552 im Abschnitt

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.